Pfizer Inc. $PFE Shares Sold by Apexium Financial LP

Apexium Financial LP cut its holdings in Pfizer Inc. (NYSE:PFE) by 16.7% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 12,158 shares of the biopharmaceutical company’s stock after selling 2,445 shares during the period. Apexium Financial LP’s holdings in Pfizer were worth $295,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. GKV Capital Management Co. Inc. acquired a new position in shares of Pfizer in the 1st quarter valued at about $27,000. North Capital Inc. acquired a new position in shares of Pfizer in the 1st quarter valued at about $28,000. Bayforest Capital Ltd acquired a new position in shares of Pfizer in the 1st quarter valued at about $28,000. Horizon Financial Services LLC acquired a new position in shares of Pfizer in the 1st quarter valued at about $35,000. Finally, WPG Advisers LLC acquired a new position in shares of Pfizer in the 1st quarter valued at about $35,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Trading Up 1.1%

Shares of NYSE:PFE opened at $27.37 on Friday. The company has a 50 day moving average of $24.67 and a 200-day moving average of $24.14. The firm has a market cap of $155.59 billion, a P/E ratio of 14.56, a P/E/G ratio of 0.88 and a beta of 0.55. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $30.43. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the prior year, the business posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Analysts Set New Price Targets

PFE has been the topic of several recent research reports. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research report on Saturday, September 27th. Citigroup lifted their price objective on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. UBS Group reiterated a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a research report on Wednesday. Finally, Bank of America lifted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Pfizer currently has an average rating of “Hold” and a consensus target price of $28.41.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.